If you’re having hormone therapy for prostate cancer, you may notice that your nipples feel sore or that your chest becomes swollen or tender. You might also feel a firmer area beneath your nipple. Enlargement of glandular breast tissue is called gynaecomastia, and it can develop when treatment changes your hormone balance. Breast tenderness may occur with or without visible enlargement. Both problems are particularly common when you take bicalutamide on its own for several months.
If these changes bother you, speak to your doctor about ways to prevent or manage them. Most breast changes are harmless, but don’t ignore a persistent hard lump, nipple discharge or changes to your skin, as these should be checked.
What Is Gynaecomastia?
Gynaecomastia is the growth of glandular breast tissue in men, rather than simply gaining fat around your chest. You may notice a firm or rubbery area beneath your nipple, tenderness or swelling on one or both sides. It can happen when prostate cancer hormone therapy changes the balance between testosterone and oestrogen activity.
The amount of swelling varies from person to person. You might notice only a small, tender area or more visible breast enlargement. This is a possible treatment side effect and doesn’t tell you whether your prostate cancer treatment is working.
Why Can Prostate Cancer Hormone Therapy Cause Breast Enlargement?
If you’re having hormone therapy for prostate cancer, you may notice that your chest feels tender or looks larger. This can happen because your treatment changes the balance between testosterone and oestrogen, allowing your breast tissue to grow.
If you’re taking bicalutamide on its own, breast changes are more common because the medicine blocks androgen receptors without necessarily lowering circulating testosterone. Some testosterone may be converted into oestrogen, contributing to increased oestrogen activity relative to androgen activity in breast tissue. This can encourage glandular growth and cause swelling or tenderness during treatment.
Which Prostate Cancer Treatments Are Most Likely to Cause Gynaecomastia?
If you’re taking bicalutamide on its own, especially at a high dose for more than six months, you’re more likely to develop breast swelling or tenderness. Other medicines, such as flutamide and oestrogen-based treatments, can also cause breast enlargement.
Your risk depends on the medicine and treatment duration. Short-term bicalutamide differs from long-term monotherapy, so ask your doctor what breast changes you might experience.
How Does Gynaecomastia Risk Differ Between Hormone Treatments?
| Treatment situation | Relative likelihood of breast changes | Important point |
| Long-term bicalutamide monotherapy | High | NICE specifically recommends preventive breast-bud radiotherapy when treatment exceeds 6 months |
| Short-term bicalutamide | Lower than prolonged monotherapy | Risk depends on duration and regimen |
| LHRH/GnRH ADT | Lower | Breast changes can occur but are less characteristic |
| ARPI (androgen-receptor pathway inhibitor) monotherapy | Increased | 2025 evidence shows substantially more gynaecomastia than ADT alone |
| ARPI + conventional androgen deprivation therapy (ADT) | Lower than ARPI monotherapy | Meta-analysis found no significant increase compared with ADT alone |
| Oestrogen-based treatment | Can be substantial | Breast enlargement is a recognised hormonal effect |
Can Standard ADT Injections Cause Breast Tenderness Too?

Yes, if you’re receiving hormone therapy injections such as goserelin, leuprorelin, triptorelin or degarelix, you may notice nipple sensitivity or breast tenderness. These treatments lower your testosterone levels, and although breast enlargement is less common than with bicalutamide taken alone, it can still happen.
If you notice these changes, let your cancer team know. They can check whether your symptoms are an expected side effect or whether another cause needs to be considered.
What Does Breast Tenderness Usually Feel Like?
If you develop breast tenderness during hormone therapy, you may notice soreness around your nipples or beneath them. Your chest might feel uncomfortable when your clothes rub against it, when you wear a seat belt or when you sleep on your front. Sometimes, your nipples may feel unusually sensitive.
You may notice tenderness before visible enlargement. Tell your cancer team early, especially if your treatment carries a higher gynaecomastia risk. They can discuss ways to manage symptoms or prevent further changes.
Can Only One Breast Be Affected?
Yes, you may notice tenderness or swelling in just one breast, while the other remains unchanged or develops swelling later. This can happen with gynaecomastia and doesn’t automatically mean something serious is wrong.
However, if you notice a new lump or unusual changes to your nipple or skin, ask your doctor to examine it. Even if you’re receiving hormone therapy, don’t assume every breast change is simply a side effect.
Is Breast Enlargement Always Gynaecomastia?
No, if your chest becomes larger during hormone therapy, it may be due to glandular breast tissue, weight gain or a combination of both. Gynaecomastia involves growth of breast tissue, while weight gain increases fat around your chest.
The difference matters because treatments for gynaecomastia won’t remove ordinary chest fat. If you’re unsure what’s causing the change, ask your doctor to examine it. Whatever the cause, it’s understandable if the change affects your confidence or how you feel about your appearance.
Clinical Note
Gynaecomastia refers to enlarged glandular breast tissue, usually centred beneath the nipple. Increased fatty tissue around the chest is different and may occur as part of treatment-related weight gain.
The two can coexist. This distinction matters because radiotherapy or tamoxifen aimed at gynaecomastia will not remove ordinary chest fat.
How Common Is Gynaecomastia With Bicalutamide?

If you take high-dose bicalutamide on its own for an extended period, breast swelling and tenderness can be very common. In a randomised trial, 35 out of 51 men taking bicalutamide alone developed gynaecomastia or breast pain. This was a combined finding, so it should not be interpreted as 35 men necessarily developing breast enlargement.
However, these figures apply to a specific treatment regimen, not every type of prostate cancer hormone therapy. Ask your doctor which medicine you’re taking and how likely it is to cause breast changes in your situation.
Research Insight
A randomised study involving 151 men compared bicalutamide alone, bicalutamide plus tamoxifen and bicalutamide plus preventive radiotherapy. Gynaecomastia or breast pain developed in 35 of 51 men receiving bicalutamide alone, compared with 4 of 50 receiving tamoxifen and 17 of 50 receiving radiotherapy. Breast pain was also reported separately in 29 of 51 men taking bicalutamide alone, compared with 3 of 50 receiving tamoxifen and 15 of 50 receiving radiotherapy.
These results show that both approaches can reduce bicalutamide-related breast symptoms. However, the trial studied bicalutamide 150 mg daily and used a single 12 Gy radiotherapy fraction, whereas NICE recommends a single 8 Gy fraction for its specified preventive regimen. These trial findings should not be extrapolated to every hormone treatment.
Can Newer Androgen-Receptor Drugs Cause Gynaecomastia?
Yes, newer medicines such as enzalutamide, darolutamide and apalutamide can cause breast enlargement, particularly when used without conventional testosterone-suppressing therapy. The risk may be different when these medicines are combined with ADT.
If you notice breast swelling or tenderness while taking one of these medicines, let your cancer team know. Don’t stop or change your treatment yourself, as your doctor can help you understand the cause and discuss suitable options.
Evidence Note
A 2025 systematic review and meta-analysis included 18 randomised controlled trials involving 5,036 patients. Androgen-receptor pathway inhibitor monotherapy was associated with substantially more gynaecomastia than conventional ADT, with a relative risk of 5.19.
In contrast, adding an androgen-receptor pathway inhibitor to ADT did not significantly increase gynaecomastia compared with ADT alone. The hormonal context therefore matters as much as the name of the drug.
Can Gynaecomastia Be Prevented Before It Starts?
Yes, sometimes. If you’re starting bicalutamide on its own for more than six months, NICE guidance recommends offering radiotherapy to both breast areas within the first month to help prevent breast swelling. This recommendation applies to a specific treatment, not every type of hormone therapy.
If you’re about to start long-term anti-androgen treatment, discuss prevention with your doctor before treatment begins. Your risk depends on the medicines you’re taking, so your care team can explain whether radiotherapy or another approach may be suitable for you.
How Does Breast-Bud Radiotherapy Prevent Gynaecomastia?
If you’re taking long-term bicalutamide on its own, a small dose of radiotherapy can be directed at the tissue behind each nipple to help prevent breast enlargement and tenderness. NICE recommends a single 8 Gy treatment for this specific situation. This is different from radiotherapy to your prostate, as the treatment targets a small area of breast tissue.
Radiotherapy can lower your risk, but it won’t prevent every case and may cause temporary skin irritation or discomfort. If you’re considering this option, your oncology team can explain the likely benefits and risks for you.
UK Guidance Note
For people starting bicalutamide monotherapy lasting longer than six months, NICE recommends offering prophylactic radiotherapy to both breast buds within the first month of treatment. The recommended regimen is a single 8 Gy fraction using orthovoltage or electron-beam treatment.
If radiotherapy does not prevent gynaecomastia, NICE advises considering weekly tamoxifen. This is an off-label use, so the risks and benefits should be discussed with the treating team.
Can Tamoxifen Prevent Breast Enlargement?

Yes, tamoxifen can help prevent or treat breast enlargement and tenderness associated with bicalutamide. It blocks oestrogen’s effects in breast tissue, and randomised studies have shown benefits. NICE recommends preventive breast-bud radiotherapy for long-term bicalutamide monotherapy and considering weekly tamoxifen if radiotherapy does not prevent gynaecomastia. Some clinical trials used daily tamoxifen, so the studied schedules should not be confused with NICE’s specific recommendation.
However, tamoxifen isn’t suitable for everyone and can increase the risk of blood clots in some people. Don’t start taking it yourself. Speak to your cancer team about whether it’s appropriate for you and which option best fits your treatment.
What If Breast Enlargement Has Already Started?
Management depends on how recently the breast symptoms began, how troublesome they are and which prostate cancer treatment you are receiving:
- Tell your treatment team early: Recent breast pain or enlargement may be more responsive to treatment than long-standing glandular tissue.
- Confirm the likely cause: Your clinician may examine the breast to distinguish gynaecomastia from chest fat or another breast condition.
- Discuss tamoxifen where appropriate: Evidence suggests it can reduce bicalutamide-related breast pain and recently developing gynaecomastia.
- Review previous prevention: If breast-bud radiotherapy was given but symptoms still developed, NICE says weekly tamoxifen can be considered.
- Do not stop cancer treatment yourself: Breast symptoms can often be managed without abandoning an otherwise appropriate cancer treatment.
- Consider specialist review for persistent enlargement: Long-standing or severe gynaecomastia that remains painful or distressing may need additional management.
- Investigate unusual features separately: A hard lump, nipple discharge, inversion, skin dimpling or axillary lump should not simply be labelled gynaecomastia.
Long-standing glandular enlargement may not disappear completely, so early discussion with your cancer team is useful.
Can Surgery Be Used for Severe Gynaecomastia?
If you’ve developed noticeable breast enlargement and it’s causing you discomfort or affecting your confidence, you may wonder whether surgery could help. If other treatments haven’t worked, your doctor may discuss an operation to remove the extra breast tissue and, sometimes, fat. However, surgery is usually not the first option, especially if your breast changes have only recently started.
Before deciding, discuss your prostate cancer treatment, general health and whether continued hormone therapy could cause further breast changes. Your cancer team can explain alternatives because many men can manage gynaecomastia without surgery.
Does Gynaecomastia Mean You Have Breast Cancer?
If you notice breast swelling during prostate cancer hormone therapy, it may be gynaecomastia, which is benign enlargement of glandular breast tissue. However, don’t assume every new breast change is treatment-related. If you find a lump in your breast or armpit, notice nipple discharge, especially if bloodstained, or develop nipple inversion, skin dimpling, a persistent nipple rash or sores, arrange prompt assessment with your GP or cancer team.
These changes don’t automatically mean you have breast cancer, so try not to jump to conclusions. Your doctor can examine the area and arrange tests, such as an ultrasound or mammogram, if needed. Even if your hormone therapy makes gynaecomastia more likely, it’s important to get any unusual or persistent changes checked.
When Should You Tell Your Prostate Cancer Team About Breast Changes?

If you’re about to start hormone therapy, ask your cancer team whether your treatment could cause breast swelling or tenderness and whether you can take steps to prevent it. This is particularly important if you’re starting long-term bicalutamide on its own. Once treatment begins, let your team know if your nipples become persistently sore or you notice breast tissue growing. You don’t need to wait until the changes become severe.
You may feel embarrassed discussing breast symptoms, but your cancer team is familiar with hormonal side effects and can help you understand your options. Tell them which medicines you take and how the changes affect you. Arrange a separate medical assessment if you notice a hard lump, nipple discharge, nipple inversion or skin dimpling rather than assuming the change is caused by your treatment.
Myth vs Fact
| Myth | Fact |
| All hormone therapy causes breast enlargement. | Risk varies greatly between treatments and is particularly high with anti-androgen monotherapy. |
| Every larger-looking chest is gynaecomastia. | Weight gain can increase chest fat without glandular breast enlargement. |
| Standard ADT injections cause gynaecomastia as often as bicalutamide alone. | Breast enlargement is generally less common with testosterone-suppressing ADT. |
| Only both breasts can be affected. | Gynaecomastia can be asymmetrical, but a new unilateral lump still needs assessment. |
| Breast swelling means the cancer treatment is working. | Gynaecomastia does not indicate treatment response. |
| Preventive breast radiotherapy is recommended for everyone starting ADT. | NICE recommends it specifically for long-term bicalutamide monotherapy. |
| Tamoxifen can simply be started over the counter. | It is a prescription medicine and its use for this indication is off-label in the UK. |
| Every breast lump during hormone therapy is harmless. | Persistent hard lumps, nipple changes, discharge or skin changes require assessment. |
Key Takeaways
- Gynaecomastia is enlargement of glandular breast tissue, not simply chest fat.
- Breast tenderness may occur before visible enlargement.
- Long-term bicalutamide monotherapy carries a particularly high risk of gynaecomastia and breast pain.
- Conventional testosterone-suppressing ADT generally carries a lower risk.
- Newer androgen-receptor pathway inhibitors can increase gynaecomastia when used as monotherapy.
- NICE recommends prophylactic breast-bud radiotherapy for bicalutamide monotherapy lasting more than six months.
- New breast lumps, nipple discharge or skin changes should be assessed rather than dismissed as treatment effects.
Frequently Asked Questions
1. What is gynaecomastia during prostate cancer hormone therapy?
Gynaecomastia is the growth of glandular breast tissue in men, causing swelling, tenderness or a firm area beneath the nipple. It can occur when hormone therapy changes the balance between testosterone and oestrogen activity.
2. Why can hormone therapy cause breast tenderness or enlargement?
Hormone therapy can change your hormone balance and affect breast tissue. Bicalutamide taken on its own is particularly associated with breast swelling and tenderness because it blocks testosterone’s effects without necessarily lowering testosterone levels.
3. Which prostate cancer treatments are most likely to cause gynaecomastia?
Bicalutamide taken on its own for several months carries a higher risk of gynaecomastia. Other treatments, including flutamide and oestrogen-based medicines, can also cause breast enlargement.
4. Can hormone therapy injections cause breast tenderness?
Yes, injections such as goserelin, leuprorelin, triptorelin and degarelix may cause nipple sensitivity or breast tenderness. Breast enlargement is less common than with bicalutamide taken alone, but it can still occur.
5. Can gynaecomastia affect only one breast?
Yes, breast tenderness or enlargement can affect one breast or both, and the changes may not develop equally. However, a new lump or unusual nipple or skin change should be examined by your doctor.
6. Can gynaecomastia be prevented during prostate cancer treatment?
Yes, prevention may be possible for men starting long-term bicalutamide on its own. NICE recommends offering radiotherapy to both breast areas within the first month of treatment to help prevent breast swelling.
7. Can tamoxifen help prevent or treat breast enlargement?
Yes, tamoxifen can help reduce breast tenderness and enlargement by blocking oestrogen’s effects on breast tissue. It is not suitable for everyone and may increase the risk of blood clots, so discuss it with your cancer team.
8. What should you do if breast enlargement has already started?
Tell your cancer team, as treatments such as tamoxifen may help with recent breast changes. Long-standing enlargement may not disappear completely, and you should not stop your prostate cancer treatment without medical advice.
9. Does gynaecomastia mean you have breast cancer?
No, gynaecomastia is usually benign, but not every breast change is caused by hormone therapy. Arrange a medical assessment if you notice a hard lump, nipple discharge or inversion, skin dimpling or persistent unusual changes.
10. When should you tell your cancer team about breast changes?
Tell your team if you develop persistent nipple tenderness, swelling or breast enlargement. Seek medical assessment for a hard lump, nipple discharge, nipple inversion or skin changes rather than assuming these are treatment side effects.
Final Thoughts: Managing Breast Tenderness and Gynaecomastia on Hormone Therapy
If you’re having hormone therapy for prostate cancer, you may notice that your nipples feel sore or your chest becomes swollen or tender. These changes can feel uncomfortable or affect your confidence, but you don’t have to manage them alone. If you’re taking bicalutamide or another hormone treatment, speak to your cancer team about ways to prevent or manage breast changes. Most gynaecomastia is benign, but ask your doctor to assess new lumps, nipple discharge or unusual skin changes.
If you’re experiencing breast tenderness, swelling or gynaecomastia during prostate cancer hormone therapy, contact Prostate Clinic London to discuss your symptoms, possible treatment-related causes and suitable management options, or to arrange a specialist consultation.
References:
- National Institute for Health and Care Excellence (2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- Perdonà, S. et al. (2005) ‘Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial’, The Lancet Oncology, 6(5), pp. 295–300. Available at: https://pubmed.ncbi.nlm.nih.gov/15863377/
- Boccardo, F. et al. (2005) ‘Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer’, Journal of Clinical Oncology, 23(4), pp. 808–815. Available at: https://pubmed.ncbi.nlm.nih.gov/15681525/
- Fagerlund, A. et al. (2015) ‘Gynecomastia in patients with prostate cancer: a systematic review’, PLoS ONE, 10(8), article e0136094. Available at: https://pubmed.ncbi.nlm.nih.gov/26308532/
- Prostate Cancer UK (2025) Breast swelling and tenderness. Available at: https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/how-hormone-therapy-affects-you/breast-swelling-and-tenderness
- Tsuboi, I. et al. (2025) ‘Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: a systematic review and meta-analysis of randomized controlled trials’, European Urology Open Science, 73, pp. 31–42. Available at: https://pubmed.ncbi.nlm.nih.gov/39935942/